Comment on, "Expression of decitabine-targeted oncogenes in meningiomas in vivo".
Neurosurg Rev
; 47(1): 681, 2024 Sep 25.
Article
in En
| MEDLINE
| ID: mdl-39317826
ABSTRACT
The study by Canisius et al. (2022) explores the expression of decitabine-targeted oncogenes (TRIM58, FAM84B, ELOVL2, DIO3) in meningiomas, aiming to evaluate decitabine's therapeutic potential for high-grade tumors. Using immunohistochemical staining and RT-PCR in over 100 patient samples, the authors found significant correlations between oncogene expression and tumor grade, with elevated ELOVL2 levels being linked to tumor recurrence. This work highlights the role of decitabine in modulating oncogene expression and suggests its potential in treating refractory meningiomas. Despite the robust methodology, limitations such as the small sample size and the lack of comprehensive molecular data were noted. Future research should incorporate larger sample sizes and advanced genomic techniques like RNA sequencing to better understand oncogenic mechanisms. The study emphasizes the need for further in situ analyses of decitabine's efficacy, setting the foundation for future neuro-oncological treatments.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oncogenes
/
Decitabine
/
Meningeal Neoplasms
/
Meningioma
Limits:
Humans
Language:
En
Journal:
Neurosurg Rev
/
Neurosurg. rev
/
Neurosurgical Review
Year:
2024
Document type:
Article
Affiliation country:
India
Country of publication:
Germany